Lexicon Pharmaceuticals (LXRX) Tops Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.04 +0.99%
Revenue Growth %: -78.9%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -78.9%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q3 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $355 thousand versus the consensus estimate of $320 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
